Aptevo Therapeutics (APVO) Trading Up 12%

Aptevo Therapeutics Inc (NASDAQ:APVO)’s share price was up 12% on Wednesday . The stock traded as high as $4.82 and last traded at $4.75. Approximately 586,000 shares traded hands during trading, an increase of 66% from the average daily volume of 352,000 shares. The stock had previously closed at $4.24.

Several equities analysts have weighed in on APVO shares. ValuEngine lowered Aptevo Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 10th. Piper Jaffray Companies restated an “overweight” rating and set a $6.00 target price on shares of Aptevo Therapeutics in a report on Thursday, October 5th.

The company has a quick ratio of 7.67, a current ratio of 7.76 and a debt-to-equity ratio of 0.19.

In related news, VP Randy Joe Maddux bought 25,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were bought at an average cost of $2.76 per share, for a total transaction of $69,000.00. Following the completion of the acquisition, the vice president now directly owns 25,000 shares in the company, valued at $69,000. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 15.60% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP raised its holdings in Aptevo Therapeutics by 8.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,056,729 shares of the biotechnology company’s stock valued at $2,187,000 after buying an additional 78,109 shares in the last quarter. Legal & General Group Plc increased its stake in shares of Aptevo Therapeutics by 11,751.3% in the second quarter. Legal & General Group Plc now owns 393,701 shares of the biotechnology company’s stock worth $815,000 after purchasing an additional 390,379 shares during the period. Finally, Precept Management LLC bought a new position in shares of Aptevo Therapeutics in the second quarter worth about $1,210,000. Institutional investors own 32.13% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.tickerreport.com/banking-finance/3126519/aptevo-therapeutics-apvo-trading-up-12.html.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.